Introduction: GLP-1 receptor agonists are valuable therapeutic agents for managing obesity and type 2 diabetes. The link between prostate cancer and obesity was described. The modulation of incretin hormone-dependent pathways may decrease the prostate cancer aggressiveness and progression. Objectives: The purpose of this study was to review and summarize the literature on the role of GLP-1 agonists in prostate cancer. Material & Methods: We performed a scoping literature review of PubMed from January 2002 to February 2025. Search terms included “glucagon-peptide like 1”, “incretin hormone”, “GLP-1 receptor agonist”, and “prostate cancer”. Secondary search involved reference lists of eligible articles. The key criterion was to identify studies that included GLP-1 receptor, incretin hormones, GLP-1 receptor agonists, and their role in prostate cancer development. Results: 77 publications were selected for inclusion in this review. The studies contained in publications allowed us to summarize the data on the role of GLP-1 receptor and it’s agonists in prostate cancer biology and development. The following review aims to discuss and provide information about the role of incretin hormones in prostate cancer pathogenesis and its clinical implication in patients with prostate cancer. Conclusion: Incretin hormone-dependent pathways play an important role in prostate cancer pathogenesis. Moreover, GLP-1 receptor agonists seems to be a promising therapeutical agents when it comes to finding new therapies in patients with more aggressive and/or advanced stages of prostate cancer.
引言：胰高血糖素样肽-1受体激动剂是治疗肥胖症与2型糖尿病的重要药物。已有研究揭示了前列腺癌与肥胖之间的关联。调节肠促胰岛素激素依赖性通路可能降低前列腺癌的侵袭性与进展程度。研究目的：本文旨在系统回顾并总结胰高血糖素样肽-1激动剂在前列腺癌中作用的相关文献。材料与方法：我们对PubMed数据库2002年1月至2025年2月的文献进行了范围综述检索。检索关键词包括"胰高血糖素样肽-1"、"肠促胰岛素激素"、"GLP-1受体激动剂"及"前列腺癌"。二次检索涵盖符合条件文章的参考文献列表。核心筛选标准为识别涉及GLP-1受体、肠促胰岛素激素、GLP-1受体激动剂及其在前列腺癌发生发展中作用的研究。结果：共纳入77篇文献进行综述。通过对这些研究数据的整合分析，我们系统总结了GLP-1受体及其激动剂在前列腺癌生物学行为与发展过程中的作用机制。本综述重点探讨肠促胰岛素激素在前列腺癌发病机制中的作用，及其在前列腺癌患者中的临床意义。结论：肠促胰岛素激素依赖性通路在前列腺癌发病机制中具有重要作用。此外，针对侵袭性较强和/或晚期前列腺癌患者的新疗法探索中，GLP-1受体激动剂显示出成为潜在治疗药物的前景。
肿瘤(癌症)患者之家